Business context and reporting period
The filing is Tivic Health Systems, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2022; the request metadata names Valion Bio, Inc., which does not match the registrant in the filing. Tivic develops non-invasive bioelectronic treatments and sells ClearUP, an FDA-approved device for sinus pain and congestion, through direct-to-consumer and retail channels.
Financial results and liquidity
Amounts below are in millions of dollars except per-share data and percentages.
| Metric | Three months ended June 30, 2022 | Three months ended June 30, 2021 | Six months ended June 30, 2022 | Six months ended June 30, 2021 |
|---|---|---|---|---|
| Revenue | $0.528 | $0.268 | $0.956 | $0.591 |
| Gross profit (loss) | $0.125 | $(0.033) | $0.196 | $(0.011) |
| Gross margin | 23.7% | (12.3%) | 20.5% | (1.9%) |
| Operating expenses | $3.143 | $1.022 | $5.454 | $2.101 |
| Net loss | $(3.018) | $(1.094) | $(5.258) | $(2.450) |
| Net loss per share | $(0.32) | $(0.46) | $(0.55) | $(1.04) |
- For the six months, operating cash use was $3.920 million, investing cash use was $0.006 million, and financing cash flow was zero. Cash declined $3.926 million to $9.049 million.
- At June 30, cash was $9.049 million, working capital was $8.0 million, and total assets were $11.026 million. Current liabilities were $2.378 million; total liabilities were $2.839 million, including operating lease liabilities. The filing reports no outstanding borrowings and an undrawn $250,000 line of credit.
- Inventory rose to $0.833 million from $0.429 million. Accounts payable increased to $1.915 million from $0.789 million.
Material changes versus prior period
- Revenue grew 97% in the quarter and 62% in the six-month period year over year. Management attributed growth primarily to increased unit sales and channel optimization. Direct-to-consumer unit sales rose 265% in the quarter and 153% for the six months, while retail unit sales fell 68% and 51%, respectively, as less profitable arrangements were exited.
- Gross profit turned positive, but operating expenses increased substantially: six-month research and development rose $0.508 million, sales and marketing rose $1.164 million, and general and administrative rose $1.681 million. Higher headcount, marketing activity, public-company costs, professional fees, and D&O insurance contributed to the increases.
- Losses widened despite revenue growth. The 2021 comparison included interest expense and other items associated with convertible debt and PPP loan forgiveness; there were no corresponding other income or expense items in 2022.
Outlook, risks, and other notable items
- Management expects substantial operating losses for at least the next two years, but believes cash and financial resources are adequate for at least 12 months from the financial statements’ issuance. It anticipates higher spending on marketing, research and development, product development, and public-company operations; no quantified revenue or earnings guidance was provided.
- Development initiatives include an ongoing 60-person sham-controlled trial of post-operative sinus surgery pain treatment and early work on a potential migraine product candidate. Management also reported new patent issuance and additional PCT applications.
- Supply shortages, longer lead times, higher component and shipping costs, inflation, and uncertain economic conditions may constrain production, increase costs, impair margins, or make revenue forecasting and future financing more difficult. The company increased inventory to support availability and pricing.
- The company has incurred recurring losses and negative operating cash flows. Additional capital may be needed, and management cautions that financing may not be available on acceptable terms or at all. The IPO proceeds were the primary recent source of liquidity; no capital was raised in the first half of 2022.
- No material litigation or contingencies were identified. The filing says disclosure controls were effective, but notes a previously reported material weakness in internal control over financial reporting; remediation efforts were underway, with management’s assessment planned for the 2022 Form 10-K.
Important facts for investors to verify
- Confirm the issuer identity: the filing is for Tivic Health Systems, Inc. (Nasdaq: TIVC), not Valion Bio, Inc.
- Assess cash runway against operating cash burn, planned spending, and management’s 12-month liquidity estimate.
- Track whether direct-to-consumer growth, channel changes, and pricing can sustain revenue and improve gross margins amid supply constraints.
- Monitor inventory and accounts payable growth, component availability, and the effect of higher fulfillment and input costs.
- Review progress on clinical and product-development programs, financing needs, and remediation of the disclosed internal-control weakness.